FIGURE 7.
A scheme of the proposed mechanisms. Sorafenib treatment increases ATF3 expression by repressing Slc7a11 expression to suppress system Xc-in cardiomyocytes, and thereby predispose cells to a state prone to ferroptosis.
A scheme of the proposed mechanisms. Sorafenib treatment increases ATF3 expression by repressing Slc7a11 expression to suppress system Xc-in cardiomyocytes, and thereby predispose cells to a state prone to ferroptosis.